Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47637 | 1.00 | SIGMAR1 (0.40) | SIGMAR1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL47603 | 0.91 | ADORA1 (0.36) | SIGMAR1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL99323 | 0.91 | ADORA1 (0.36) | SIGMAR1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL47599 | 0.91 | ADORA1 (0.36) | SIGMAR1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL18566580 | 0.91 | ADORA1 (0.36) | SIGMAR1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14296232 | 0.87 | CTSB (0.31) | CTSBCTSSCTSK | |
| SCHEMBL47612 | 0.87 | CHRM2 (0.36) | SIGMAR1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL47613 | 0.87 | CHRM2 (0.36) | SIGMAR1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL47614 | 0.83 | CTSB (0.34) | CTSBCTSSCTSKF2 | |
| SCHEMBL47620 | 0.83 | CTSB (0.34) | CTSBCTSSCTSKF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-07-05 | — | — | US | disclosed |
| US-9919033-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-03-20 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2017-03-02 | — | — | US | disclosed |
| US-9511122-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-12-06 | — | — | US | disclosed |
| US-20160206702-A1 | PEGylated Recombinant Human Growth Hormone Compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-07-21 | — | — | US | disclosed |
| US-9272048-B2 | PEGylated recombinant human growth hormone compounds | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2016-03-01 | — | — | US | disclosed |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ASCENDIS PHARMA INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2015-02-26 | — | — | US | disclosed |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2015-01-08 | — | — | US | disclosed |
| US-8906847-B2 | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA A/S (DK) | 2014-12-09 | — | — | US | disclosed |
| US-20140323402-A1 | Protein Carrier-Linked Prodrugs | Ascendis Phama A/S (DK) | 2014-10-30 | — | — | US | disclosed |
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-20140243254-A1 | Polymeric Hyperbranched Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-08-28 | — | — | US | disclosed |
| US-20120322721-A1 | DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2012-12-20 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA AS (DK) | 2011-05-12 | — | — | US | disclosed |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ABCB11, SLCO1B1, SLC7A1 | SIGMAR1 277/4885CHRM2 2290/4885CHRM4 3771/4885 |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | SIGMAR1 4036/4885CHRM2 1348/4885CHRM4 1388/4885 |
| US-20120322721-A1 | DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER | GHRHR, GHSR, GCG | SIGMAR1 3617/4885CHRM2 3524/4885CHRM4 4341/4885 |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | SIGMAR1 1722/4885CHRM2 2446/4885CHRM4 3317/4885 |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ADAMTS13, ADAMTS5, TNF | SIGMAR1 4316/4885CHRM2 3245/4885CHRM4 2796/4885 |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | SIGMAR1 92/4885CHRM2 576/4885CHRM4 1331/4885 |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | SIGMAR1 3617/4885CHRM2 3524/4885CHRM4 4341/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | SIGMAR1 92/4885CHRM2 576/4885CHRM4 1331/4885 |
| US-20110112021-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | GHRHR, GHITM, GHSR | SIGMAR1 3854/4885CHRM2 4774/4885CHRM4 4775/4885 |
| US-20160206702-A1 | PEGylated Recombinant Human Growth Hormone Compounds | GHRHR, GHITM, GHSR | SIGMAR1 3854/4885CHRM2 4774/4885CHRM4 4775/4885 |
| US-20140243254-A1 | Polymeric Hyperbranched Carrier-Linked Prodrugs | P4HA1, CYP8B1, PAH | SIGMAR1 189/4885CHRM2 3054/4885CHRM4 3930/4885 |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | SIGMAR1 95/4885CHRM2 580/4885CHRM4 1332/4885 |
| US-20140323402-A1 | Protein Carrier-Linked Prodrugs | SLC6A7, PRAP1, PELP1 | SIGMAR1 1827/4885CHRM2 4289/4885CHRM4 4647/4885 |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | SIGMAR1 3617/4885CHRM2 3524/4885CHRM4 4341/4885 |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | SIGMAR1 4036/4885CHRM2 1348/4885CHRM4 1388/4885 |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | IFNG, IFNAR1, IRF3 | SIGMAR1 157/4885CHRM2 4389/4885CHRM4 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.